Mumbai, India – GNH India, an award-winning global pharmaceutical wholesaler, continues to redefine the landscape of clinical trial supplies by offering reliable and high-quality comparator and biosimilar sourcing from India. With over a decade of expertise, GNH India is paving the way for cost-effective and compliant solutions in the rapidly growing biosimilars market, addressing global demand with unmatched precision and trust.

As the biosimilars industry in India thrives, GNH India stands out as a pioneer, tackling longstanding challenges in sourcing comparators and biosimilars for clinical trials. Emerging markets like India have faced skepticism due to concerns about equivalence with innovator drugs from traditional markets like the US and EU. However, GNH India is changing this narrative by delivering WHO cGSDP-certified products and adhering to stringent global quality standards. The company’s robust supply chain and meticulous quality management systems ensure that every product meets the highest benchmarks for safety and efficacy.

“India’s biosimilar market is poised for exponential growth, with projections estimating it to reach $12 billion by 2025,” said Dr. Piyush Gupta, Associate Director of Business Development at GNH India. “Our mission is to bridge the gap between affordability and quality, making India a trusted source for comparators and biosimilars in global clinical trials.”

GNH India’s comprehensive services include clinical trial supplies, investigational medical products, and biologics, supported by a network that spans over 180 countries and a portfolio of more than 135,000 product lines. The company’s state-of-the-art facilities in Mumbai have been audited and praised for their precision, with quality systems comparable to top operational sites in the US and EU. A recent audit highlighted GNH’s knowledgeable staff and commitment to continuous improvement, reinforcing its reputation as a reliable partner.

The global demand for biosimilars is surging, driven by the expiration of patents on blockbuster biologics and the need for cost-effective healthcare solutions. India, with its thriving biosimilar ecosystem and 98 approved biosimilars—the highest globally—offers a unique opportunity to meet this demand. GNH India leverages this potential by providing smart sourcing solutions, reducing costs by up to 50% compared to traditional markets, while ensuring compliance with international regulations.

“Smart sourcing is about delivering value without compromising quality,” Dr. Gupta added. “By sourcing comparators and biosimilars from India, we help our clients achieve significant cost savings while maintaining the integrity of their clinical trials.”

GNH India’s commitment to excellence is further evidenced by its certifications in GDP, GSDP, GxP, and ISO standards, ensuring that the right medicine reaches the right patient at the right time. As the global biosimilars market is projected to grow to $25 billion by 2020 and beyond, GNH India is well-positioned to lead the charge, offering innovative solutions that empower biopharmaceutical companies worldwide.

For more information about GNH India’s services or to explore partnership opportunities, visit www.gnhindia.com.